Company: KROS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001664710-25-000070
Chunk: 260

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 1
Chunk 260
---
 ended June 30, 2024. The increase of $13.4 million was primarily due to (i) an increase of $14.9 million in elritercept-related expenses, primarily driven by an increase of $8.7 million in clinical spend associated with our ongoing Phase 2 clinical trials, one in patients with MDS and one in patients with myelofibrosis, and the advancement of a Phase 3 clinical trial in patients with MDS, and an increase of $6.2 million in manufacturing activities; (ii) an increase of $5.0 million related to personnel expenses, which includes an increase of $1.7 million of additional stock-based compensation costs, primarily driven by increased severance costs; and (iii) a net increase of $2.4 million in facilities, supplies, professional fees and other expenses. These increases were partially offset by (a) a decrease of $4.3 million of KER-065-related expenses, primarily driven by a net decrease of $3.6 million in manufacturing and preclinical activities and a decrease of $0.8 million in clinical spend associated with our Phase 1 clinical trial; (b) a decrease of $2.2 million of cibotercept-related expenses, primarily driven by a decrease of $2.4 million in clinical spend associated with our Phase 2 clinical trial, partially offset by an increase of $0.2 million in manufacturing and preclinical activities; and (c) a decrease of $2.4 million in preclinical and development fees related to general pipeline development.

General and Administrative Expenses 

General and administrative expenses were $25.0 million for the six months ended June 30, 2025, compared to $20.3 million for the six months ended June 30, 2024. The increase of approximately $4.7 million was primarily due to a net increase of $4.9 million in professional fees, insurance, facilities, supplies and other expenses to support the growth of our business, partially offset by a decrease of $0.2 million in personnel expenses, which includes a decrease of $1.2 million additional stock-based compensation costs, partially offset by a net increase of $1.0 million in salaries and bonus, severance, benefits and other payroll costs.

Total Other Income, Net

Total other income, net was $13.4 million for the six months ended June 30, 2025, compared to $10.6 million for the six months ended June